Lasmiditan hemisuccinate

半琥珀酸拉米地坦

Report date: 2026/03/11 20:02:12
NMEFirst In Class

Base Information

Drug NameLasmiditan hemisuccinate
Drug Alias Name拉司米地坦lasmiditanlasmiditanum拉米替坦LasmiditanSuccinate +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 1f (5-HT1f) receptor agonists
TargetsSerotonin 1f (5-HT1f) receptor
Therapy Area/IndicationsDrug-Related Side Effects and Adverse ReactionsMigraine Disorders
Global Approved IndicationsMigraine Disorders
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/10/11
Country/TerritoryCzechiaBelgiumCanada +[24] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaDiscontinued
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly Japan KkEli Lilly And CompanyDaiichi Sankyo Co Ltd +[4] 
Inactive CompaniesColucid Pharmaceuticals IncLilly Del Caribe IncIldong Pharmaceutical Co Ltd +[5] 
Active IndicationsMigraine Disorders
Inactive IndicationsDrug-Related Side Effects and Adverse Reactions

Other Information

ATC CodeN02C
Related LinksWikipediaDrugBankKEGG